A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC.
采用 EGFR-MET 双特异性抗体和 HER3 ADC 联合策略克服 NSCLC 中的奥希替尼耐药性。
期刊:Cellular Oncology
影响因子:4.8
doi:10.1007/s13402-025-01152-8
Wang Yuanyuan, Guo Haoyue, Han Ruoshuang, Wu Yuhan, He Taiping, Diao Meng, Xiong Anwen, Zhou Fei, Cheng Lei, Zhao Chao, Li Xuefei, Zhou Caicun